

#### **NEW PROGRAM ANNOUNCEMENT**

# **Early Phase Clinical Trials: Canada**

(Rolling applications)

Funding for clinical trials and clinical trial sub-studies that accelerate the development of therapeutics for neurodegenerative diseases of aging

Maximum \$1,500,000 over up to 4 years

# **NEW for 2018**

- The Institute has updated which tools are in scope.
   Please read What We Fund before applying to ensure your project is in scope
- The Early Phase Clinical
  Trials: Canada program will
  be run on a rolling basis

# Institute definition of neurodegenerative diseases of aging

- Alzheimer's disease
- Dementia with Lewy bodies
- Frontotemporal dementia
- Multiple system atrophy
- Parkinson's disease
- Progressive supranuclear palsy
- Vascular contributions to the above diseases
- Prodromes to the above diseases

#### **ELIGIBILITY CRITERIA**

#### Principal applicant must be:

- 1. At or above the level of Assistant Professor or equivalent
- 2. Affiliated with a Canada Revenue Agency-qualified donee institution located in Canada

#### Project must be:

- 1. A clinical trial(s) and/or a clinical trial sub-study(s) that accelerates the development of therapeutics for neurodegenerative diseases of aging
- 2. The development of a therapeutic and/or tool

### **APPLICATION PROCESS**

- 1. Review all program information and determine whether your project is in scope
- 2. Register or sign in to our online grants management system
- 3. Complete and submit a Letter of Intent (LOI)
  - o If selected, applicants will be invited to submit a full Proposal
  - Applicants can expect to receive the outcome of their LOI application within ~2 months of submission
- 4. Complete and submit a full Proposal (by invite only)







## FOR MORE INFORMATION